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Introduction
Growth differentiation factor 15 (GDF15), also known as 
PL74, macrophage inhibitory cytokine- 1 (MIC- 1), placental 
bone morphogenetic protein (PLAB), prostate- derived 
 factor (PDF), placental transforming growth factor- β 
(PTGFB), and nonsteroidal anti- inflammatory drug acti-
vated gene- 1 (NAG- 1), is a pleiotropic cytokine belonging 
to the bone morphogenetic protein (BMP) subfamily of 
the transforming growth factor- β (TGF- β) superfamily 
[1–7]. Various types of cells express GDF15 in response 
to cellular stresses such as inflammation and ischemia, 
although its steady- state expression is almost completely 
restricted to the placenta [5]. In cells, GDF15 is initially 
translated as a 62- kD proprotein, and it is then processed 
by a furin- like protease to produce 25- kD mature peptides 
that form a disulfide- linked homodimer [8]. Specific 
 receptors and signaling pathways for GDF15 have still 
not been determined; however, roles in stress responses, 
inflammation, tissue repair after acute injury, energy 
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Abstract
Growth differentiation factor 15 (GDF15) is a pleiotropic cytokine that belongs 
to the transforming growth factor- β superfamily. Elevated serum concentrations 
of this cytokine have been reported in patients with various malignancies. To 
assess the potential roles of GDF15 in hematologic malignancies, we measured 
its serum levels in patients with these diseases. We found that serum GDF15 
levels were elevated in almost all these patients, particularly in patients with 
primary myelofibrosis (PMF). Immunohistochemical staining of bone marrow 
(BM) specimens revealed that GDF15 was strongly expressed by megakaryocytes, 
which may be sources of increased serum GDF15 in PMF patients. Therefore, 
we further assessed the contribution of GDF15 to the pathogenesis of PMF. 
Recombinant human (rh) GDF15 enhanced the growth of human BM mesen-
chymal stromal cells (BM- MSCs), and it enhanced the potential of these cells 
to support human hematopoietic progenitor cell growth in a co- culture system. 
rhGDF15 enhanced the growth of human primary fibroblasts, but it did not 
affect their expression of profibrotic genes. rhGDF15 induced osteoblastic dif-
ferentiation of BM- MSCs in vitro, and pretreatment of BM- MSCs with rGDF15 
enhanced the induction of bone formation in a xenograft mouse model. These 
results suggest that serum levels of GDF15 in PMF are elevated, that megakaryo-
cytes are sources of this cytokine in BM, and that GDF15 may modulate the 
pathogenesis of PMF by enhancing proliferation and promoting osteogenic dif-
ferentiation of BM- MSCs.
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homeostasis, systemic iron metabolism, and malignancy 
have been suggested [9, 10].
Serum concentrations of GDF15 increase during preg-
nancy as a result of strong expression in the placenta 
[5]. In pathological conditions, elevated serum GDF15 
levels have been identified as an independent risk factor 
for acute coronary heart diseases [11, 12]. In addition, 
the serum GDF15 concentration is notably increased in 
patients with glioma, prostate, colorectal, or pancreatic 
cancers, and GDF15 was recently described as one of the 
20 biomarkers that best define the malignant phenotype 
of numerous tumors [9, 10, 13]. However, its biological 
roles in cancers are complex and poorly understood; some 
studies have documented its protumorigenic activities, 
whereas others have demonstrated its antitumorigenic 
activities, which appear to be dependent on the types 
and stages of cancers [9].
In hematopoietic diseases, serum GDF15 levels are 
 remarkably elevated in patients with dyserythropoietic 
disorders such as β- thalassemia, congenital dyserythropoi-
etic anemia type I, and refractory anemia with ring si-
deroblasts, a subtype of myelodysplastic syndromes (MDS) 
[14–17]. Common features of these diseases include sys-
temic iron overload and ineffective erythropoiesis, and 
the major source of the serum GDF15 in these diseases 
is assumed to be erythroid cells [14]. Recently, serum 
GDF15 levels in polycythemia vera (PV) and essential 
thrombocythemia (ET), which are two types of myelo-
proliferative neoplasm (MPN), were shown to be increased 
in comparison with the levels in healthy controls [18]. 
In addition, serum levels of GDF15 were reported to be 
elevated in patients with multiple myeloma (MM), and 
bone marrow (BM) mesenchymal stromal cells (MSCs) 
from these patients were shown to express high levels of 
GDF15 [19–22]. It was speculated that GDF15 secreted 
from these cells may play roles in the pathogenesis of 
MM by enhancing the tumor- initiation and self- renewal 
potential of MM cells [21].
In this study, we evaluated serum levels of GDF15 in 
patients with various hematologic diseases. We found 
that patients with primary myelofibrosis (PMF) showed 
very high serum GDF15 levels, which prompted us to 
further investigate the source of GDF15 in the BM, and 




Diosgenin and pholbol- 13 myristate- 12 acetate (PMA) 
were purchased from Sigma- Aldrich (St. Louis, MO). 
Hemin was obtained from Alfa Aesar (Ward Hill, MA). 
Recombinant human growth differentiation factor 15 
 (rhGDF15) was purchased from R&D Systems 
(Minneapolis, MN). Recombinant human transforming 
growth factor- β1 (rhTGF- β1), stem cell factor (SCF), 
interleukin- 3 (IL- 3), and Flt3- ligand (Flt3- L) were pur-
chased from Wako Pure Chemical Industries (Osaka, 
Japan). Thrombopoietin (TPO) was provided by Kyowa 
Hakko Kirin (Tokyo, Japan).
Clinical materials
Serum samples collected from 14 healthy volunteers 
 (median age, 35 years; range, 30–46 years) and 128 adult 
patients with various hematologic malignancies at Kyoto 
University Hospital from 2006 to 2015 were used. Diagnoses 
of these patients were basically based on the WHO 
Classification of Tumors of Hematopoietic and Lymphoid 
Tissues [23]. Some of the patients had received chemo-
therapy before serum collection; however, patients in 
complete remission were excluded. The samples were stored 
at −80°C until cytokine assays were performed. The BM 
biopsy samples were obtained from patients with PMF 
and ET. As normal morphology controls, BM specimens 
obtained from patients with diffuse large B- cell lymphoma 
(DLBCL) and gastric cancer without BM involvement were 
used. Written informed consent for experimental use of 
their specimens was obtained from all the patients. This 
study was approved by the ethics committee of Kyoto 
University Graduate School and the Faculty of Medicine 
of Kyoto University.
Determination of serum GDF15 levels
The concentrations of GDF15 in the collected serum sam-
ples and culture supernatants were measured by enzyme- 
linked immunosorbent assay (ELISA) in duplicates by 
using a human GDF15 DuoSet ELISA Development kit 
(R&D Systems), according to the instructions of the 
manufacturer.
Detection of GDF15 protein in the BM
The BM specimens were fixed in 10% buffered formalin, 
processed according to conventional histological tech-
niques, embedded in paraffin, and stained with hema-
toxylin and eosin. Immunohistochemical staining for 
GDF15 was performed using rabbit polyclonal antibodies 
against human GDF15 (1:100, anti- human HPA011191; 
Atlas Antibodies, Stockholm, Sweden) on an automated 
slide stainer (Ventana XT System Benchmark; Ventana 
Medical Systems, Tucson, AZ). Images were acquired 
 using a BioZero BZ- 8100 microscope (Keyence, Osaka, 
Japan).
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Cell lines, culture conditions and in vitro cell 
differentiation and proliferation assays
HEL (JAK2 V617F positive human erythroleukemia) cells 
were cultured in RPMI 1640 (Nacalai Tesque, Kyoto, 
Japan) supplemented with 10% fetal bovine serum (FBS; 
Sigma- Aldrich) and 100 U/mL penicillin and 100 μg/mL 
streptomycin (Nacalai Tesque) in a humidified 5% CO2 
incubator at 37°C. To induce megakaryocytic differentia-
tion, HEL cells were grown in the presence of 10 μmol/L 
diosgenin or 10 nmol/L PMA. Additionally, to induce 
erythroid differentiation, the cells were treated with 
50 μmol/L hemin. After 96 h of culture, approximately 
3 × 104 cells were collected onto a glass slide by cen-
trifugation for 4 min at 600g using Cytospin3 (Thermo 
Shandon, Pittsburgh, PA). After air- drying, the slides were 
stained with May- Grunwald- Giemsa (Sigma- Aldrich), and 
observed using light microscopy.
Hematopoietic progenitor cell 
expansion assay
Human bone marrow mesenchymal stromal cells 
 (BM- MSCs) were purchased from AllCells (Emeryville, CA) 
and cultured in advanced- minimal essential medium 
(Thermo Fisher Scientific Inc., Waltham, MA) supplemented 
with 5% fetal bovine serum (FBS, Thermo Fisher Scientific), 
100 μmol/L ascorbic acid (Wako Pure Chemical Industries), 
2 mmol/L l- glutamine, 100 U/mL penicillin, and 100 μg/
mL streptomycin (all from Gibco, Carlsbad, CA) as described 
previously[24–27]. Normal human BM mononuclear cells 
were separated from BM aspirates (AllCells) using Ficoll- 
Hypaque- Plus solution (GE Healthcare, Tokyo, Japan). 
CD34+HPCs (Hematopoietic progenitor cell) were isolated 
from BM mononuclear cells by using anti- CD34 immuno-
magnetic microbeads (Miltenyi Biotec, Bergisch Gladbach, 
Germany). For in vitro HPC expansion assays, culture- 
expanded human BM- MSCs (2 × 104 cells/well) were seeded 
in a 24- well culture plate. Then, CD34+ HPCs isolated from 
normal human BM mononuclear cells were applied 
(0.6 × 103 cells/well) and co- cultured in StemSpan Serum- 
free Expansion Medium (SFEM; StemCell Technologies, 
Vancouver, Canada) supplemented with 100 ng/mL SCF, 
100 ng/mL Flt3- L, 20 ng/mL IL- 3, and 50 ng/mL TPO. 
After 10 days of co- culture, the number and surface marker 
expression of the expanded hematopoietic cells were deter-
mined by flow cytometry with fluorescence- conjugated an-
tibodies. Fluorescein isothiocyanate (FITC)- conjugated 
anti- human CD45 and phycoerythrin (PE)- conjugated mouse 
anti- human CD34 antibodies were purchased from BD 
Pharmingen (San Diego, CA), and allophycocyanin (APC)- 
conjugated mouse antibody against human CD38 was pur-
chased from Bioscience (San Diego, CA). Each analysis 
included corresponding FITC- or PE- conjugated isotype 
controls. Dead cells were excluded by staining with pro-
pidium iodide. All data were acquired using a FACSCanto 
II (Becton Dickinson, San Jose, CA), and 10,000 events per 
sample were collected. Acquired data were subsequently 
analyzed with FlowJo software (Tree Star, Ashland, OR).
Culture conditions of normal human 
primary dermal fibroblasts
Normal human primary dermal fibroblasts (NHDF) were 
purchased from Lonza (Walkersville, MD) and maintained 
in fibroblast growth medium- 2 (FGM- 2) BulletKit (CC- 3132, 
Lonza) in a humidified 5% CO2 incubator at 37°C. For 
proliferation assays, NHDFs were plated at a density of 
2 × 104 cells/well in 6- well plates with FGM- 2 in five rep-
licates. After 24 h of incubation, the culture medium was 
replaced with Dulbecco’s modified Eagle’s medium (DMEM, 
Nacalai Tesque) containing 1% FBS in the presence of 
30 ng/mL rhGDF15 or 2 ng/mL rhTGF- β1 in triplicate. 
Then, after an additional 48, 72, or 96 h of culture, the 
cells were trypsinized, resuspended, and counted in a hemo-
cytometer by using Trypan blue exclusion. For growth 
inhibition assays, NHDFs were treated with either 1 μg/
mL anti- GDF15 neutralizing mAb (clone 147627, MAB957, 
R&D Systems) or the same concentration of control isotype- 
matched mouse IgG [28]. For gene expression analysis, 
NHDF cells were treated with 50 ng/mL rhGDF15 or 2 ng/
mL rhTGF- β1 in serum- free DMEM for 3 days.
Evaluation of proliferation and 
differentiation of human BM- MSCs in vitro
Human BM- MSCs that had just been thawed were 
seeded at a density of 2 × 104 cells/well in 6- well plates 
with the medium in five replicates. After 24 h of 
 incubation, the cell culture medium was replaced with 
MSC growth medium with or without rhGDF15 (30 
ng/mL). Adherent cells were detached from the culture 
dish and viable cells were counted using Trypan blue 
exclusion after 96, 144, and 192 h without changing 
the medium.
To analyze the osteogenic differentiation of human 
 BM- MSCs, the cells were seeded at a density of 2 × 105 
cells in 8 mL of the medium per 10- cm dish until con-
fluent. The cells were then treated with 30 ng/mL rhGDF15 
in the medium, which was replaced every 3–4 days. After 
4 weeks of culture, the cells were washed with PBS, fixed 
in 60% isopropanol, and stained for mineralized deposi-
tion with 1% Alizarin Red S dye. The area of the min-
eralized deposits was quantified using ImageJ software 
(National Institutes of Health, Bethesda, MD). To analyze 
adipogenic differentiation, the lipid droplets in the cells 
1561© 2015 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.  
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were stained with Oil Red O after 2 weeks of culture in 
MSC growth medium in the presence or absence of 30 
ng/mL rhGDF15.
In vivo bone formation assays
In vivo bone formation assays were performed as previ-
ously described [29, 30]. In brief, a 100- μL cell suspension 
containing approximately 1 × 106 BM- MSCs was seeded 
on a hydroxyapatite- poly d, l- lactic- co- glycolic acid com-
posite block type scaffold (HA scaffold; GC Corporation, 
Tokyo, Japan) and cultured at 37°C in an atmosphere 
containing 5% CO2 for 1 h, and the scaffold was then 
implanted subcutaneously into the dorsal surface of 7- to 
9- week- old nonobese/severe combined immunodeficiency 
(NOD/SCID) mice. At 10 weeks after implantation, the 
scaffold was harvested and histological analysis was per-
formed. The area of formed bone in five different fields 
viewed at ×100 magnification was quantified using ImageJ 
software as previously described [30]. The results are 
 expressed as the ratio of the total bone formation area 
to the total implant area. All mice were maintained under 
specific pathogen- free conditions at the Institute of 
Laboratory Animals, Kyoto University. The animal experi-
ments were approved by the Committee on Animal 
Research of Kyoto University.
Immunoblotting analysis
Cell extracts were prepared using Mammalian Protein 
Extraction Reagent (M- PER; Thermo Fisher Scientific) 
with complete protease inhibitor cocktail (Thermo Fisher 
Scientific)  according to the manufacturer’s instructions. 
Western blotting was performed by standard methods with 
anti- phospho p42/p44 MAPK (ERK1/2) (Thr202/Tyr204) 
(Cell Signaling Technology Inc., Danvers, MA), anti- total 
ERK1/2, anti- Runx2 (1:1000, ab76956, Abcam, Cambridge, 
MA), anti- Osterix (SP7) (1:1000, ab22552, Abcam), and 
anti- β- actin (1:1000, A5441, Sigma- Aldrich) antibodies.
Quantitative real- time PCR analysis
Total RNA was extracted using TRIzol (Thermo Fisher 
Scientific) and reverse- transcribed into cDNA by using 
PrimeScript RT Master Mix (Takara Bio, Shiga, Japan), 
according to the manufacturer’s instructions. Real- time 
PCR was performed with SYBR Premix Ex Taq II (Takara 
Bio) and with a Thermal Cycler Dice Real Time System 
TP850 (Takara Bio). The primer sequences used are listed 
in Supplementary Table S1. The gene  expression data 
were normalized against those of β- actin. Each experi-
ment was performed in triplicate cultures, and results 
were averaged.
Statistical analyses
Unpaired Student’s t- test or Fisher’s exact test was used 
for analyses. Data in bar graphs indicate the mean ± SE 
(n = 3), and all experiments were performed in triplicates 
or duplicates and repeated at least three times. Statistical 
significance is expressed as follows: **P < 0.01; *P < 0.05; 
n.s., not significant.
Results
Serum GDF15 levels are remarkably elevated 
in patients with primary myelofibrosis
We measured the serum levels of GDF15 in 14 healthy 
volunteers and in 128 patients with various hematopoietic 
malignancies, including acute myeloid leukemia (AML; 
n = 7), MDS (n = 28), chronic myelogenous leukemia 
(CML, n = 4), PMF (n = 13), PV (n = 22), ET (n = 20), 
MM (n = 10), malignant lymphoma (ML; n = 14), acute 
lymphoblastic leukemia (ALL; n = 3), and adult T- cell leu-
kemia (ATL; n = 7). The median serum GDF15 levels in 
all these disease categories were significantly elevated relative 
to the levels in healthy controls: AML, 4078 pg/mL; MDS, 
3249 pg/mL; CML, 1393 pg/mL; PMF, 5425 pg/mL; PV, 
2458 pg/mL; ET, 2732 pg/mL; MM, 2074 pg/mL; ML, 
2197 pg/mL; ALL, 1780 pg/mL; ATL, 2213 pg/mL; and 
healthy controls, 505 pg/mL (Fig. 1). Among these patients, 
we noticed that the levels of serum GDF15 were remarkably 
high in those with PMF, a subtype of MPN, and the levels 
were significantly higher than the levels of the other types 
of MPN. PMF patients with advanced disease with more 
severe anemia tended to show higher serum GDF15 levels 
(Table S2). Therefore, in the subsequent experiments, we 
focused on the roles of GDF15 in the pathogenesis of PMF.
Expression of GDF15 protein in BM 
predominantly occurs in megakaryocytes
Previous studies have shown that GDF15 is produced 
by erythroid cells, macrophages, and MSCs among cell 
populations in the BM [4, 14, 20–22]. To investigate 
the source of elevated serum GDF15 in patients with 
PMF, we examined GDF15 protein expression in paraffin- 
embedded BM biopsy specimens. Microscopic examina-
tion of hematoxylin and eosin- stained specimens of 
patients with PMF showed increased numbers of mega-
karyocytes (Fig. 2A). Immunohistochemistry (IHC) 
 revealed that GDF15 was expressed predominantly in 
these megakaryocytes (Fig. 2B and C). Apart from these 
megakaryocytes, which were clearly distinguishable owing 
to their large sizes, much smaller GDF15- positive cells 
with round or spindle shape were also observed 
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sporadically (Fig. 2C and D). Strong GDF15 expression 
in megakaryocytes was also observed in specimens of 
patients with ET (Fig. 2E) and specimens of patients 
with DLBCL without BM involvement (Fig. 2F). Similar 
findings were observed in nondecalcified BM clot sec-
tions from patients with ET and localized gastric cancer 
without BM involvement (Fig. S1).
GDF15 is upregulated during 
megakaryocytic differentiation of HEL cells
Proliferation of megakaryocytes in the BM is one of the 
characteristic features of PMF. To investigate the 
expression of GDF15 in megakaryocytic cells in vitro, 
we used a human erythroleukemia cell line, HEL. This 
cell line differentiates toward the megakaryocytic lineage 
in response to diosgenin or PMA, and it differentiates 
toward the erythroid lineage in response to hemin [31–33]. 
Consistent with megakaryocytic differentiation, the cell 
size increased, some of the cells were multinucleated 
(Fig. 3A–D), and cell surface expression of CD235 
 decreased (Fig. S2) after 144 h of incubation with dios-
genin or PMA. Cell surface expression of CD41, a mega-
karyocytic marker, slightly increased after incubation with 
diosgenin, and it clearly increased after incubation with 
PMA (Fig. S2).
Figure 1. Serum Growth differentiation factor 15 (GDF15 ) levels in patients with various hematological malignancies. Serum concentrations of 
GDF15 were measured by ELISA in 14 normal subjects and 128 patients with various hematopoietic malignancies. Each individual sample was assayed 
in duplicate. The box and central bars show interquartile ranges and medians, whereas whiskers on bars above and below the boxes indicate the 90th 
and 10th percentiles. *P < 0.05; **P < 0.01. Asterisks above the bars indicate significant increases in comparison with normal subjects. AML, acute 
myelogenous leukemia; MDS, myelodysplastic syndromes; CML, chronic myelogenous leukemia; PMF, primary myelofibrosis; PV, polycythemia vera; 
ET, essential thrombocythemia; MM, multiple myeloma; ML, malignant lymphoma; ALL, acute lymphoblastic leukemia; ATL, adult T- cell leukemia/
lymphoma.
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We examined GDF15 mRNA expression and protein 
secretion during HEL cell differentiation. Quantitative 
real- time PCR revealed that GDF15 mRNA expression 
was significantly upregulated during diosgenin- induced 
differentiation toward the megakaryocytic lineage in com-
parison with untreated HEL cells (Fig. 3E). Furthermore, 
the GDF15 concentration in the culture medium of 
diosgenin- stimulated HEL cells significantly and progres-
sively increased from 120 to 144 h relative to that in 
the culture medium of unstimulated cells (Fig. 3F). Similar 
results were obtained when we used PMA to induce 
megakaryocytic differentiation in these cells (Fig. 3G). 
In contrast, the amount of GDF15 in the culture super-
natants of HEL cells differentiated toward the erythroid 
lineage by hemin decreased on a per- cell basis as a result 
of an increase in cell number (Fig. 3H). These results 
indicate that megakaryocytic HEL cells are able to syn-
thesize GDF15.
GDF15 enhances the capacity of BM- MSCs to 
support HPC proliferation
Because GDF15 has been recognized as a stress cytokine 
that protects cells and tissues from various cellular 
stresses and has been reported to support the growth 
of various types of cells, we hypothesized that in PMF, 
GDF15 is produced to rescue the impaired BM envi-
ronment to support hematopoiesis [9, 10]. To test this 
hypothesis, we examined the effect of rhGDF15 on the 
proliferation and differentiation of HPCs. As previously 
reported, CD34+ HPCs from human BM cannot effi-
ciently proliferate in the absence of feeder cells, but 
they proliferate in the presence of human BM- MSCs 
as feeder cells [26, 34, 35]. In the absence of these 
feeder cells, GDF15 did not support proliferation of 
HPCs, but rather suppressed their growth (Fig. 4A  upper 
panel, B). Next, we treated BM- MSCs with 30 ng/mL 
Figure 2. Histological examination of Growth differentiation factor 15 (GDF15) expression in bone marrow (BM) specimens. (A) Hematoxylin and 
eosin staining and (B–F) immunohistochemical staining for GDF15. (A–D) BM biopsy specimens from patients with primary meylofibrosis and (E) 
essential thrombocythemia. (F) A BM biopsy specimen with normal morphology obtained from a patient with diffuse large B- cell lymphoma without 
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rhGDF15 for 3 days and used these cells as feeder cells 
in a direct contact co- culture system with HPCs. After 
10 days of co- culture, adherent and nonadherent cells 
were collected, and the number of the cells was cal-
culated using flow cytometry and a cell counter (Fig. 4A 
lower panel). CD45+ total hematopoietic cells expanded 
more effectively when co- cultured with GDF15- 
pretreated human BM- MSCs than when co- cultured 
with untreated human BM- MSCs (Fig. 4C). However, 
the ratios of total CD45+CD34+ HPCs, CD45+CD34+ 
CD38− immature HPCs and CD45+CD34+CD38+ less 
immature HPCs among the total CD45+ cells were 
unchanged (Fig. 4D). Taken together, these results in-
dicate that GDF15- pretreated BM- MSCs possess the 
potential to support the proliferation of HSCs without 
affecting differentiation.
Figure 3. Expression of Growth differentiation factor 15 (GDF15) during megakaryocytic differentiation of HEL cells. (A−D) May- Grunwald- Giemsa 
staining (original magnification, ×400). HEL cells were cultured in the presence of (A) control solvent, (B) 10 μmol/L diosgenin, (C) 10 nmol/L PMA, or 
(D) 50 μmol/L hemin for 96 h. (E) Expression of GDF15 mRNA in HEL cells during megakaryocytic differentiation by diosgenin. Cells were treated with 
10 μmol/L diosgenin for 48, 72, 96, 120, and 144 h, and GDF15 mRNA levels were measured by quantitative real- time PCR. The relative expression 
level of GDF15 was normalized to that of β-actin and is shown relative to the expression levels of the control. (F–H) GDF15 protein secretion levels in 
the culture supernatant determined by ELISA. HEL cells were cultured in the presence of (F) 10 μmol/L diosgenin for 24, 48, 72, 96, 120, and 144 h, 
(G) 10 nmol/L PMA for 96 h, or (H) 50 μmol/L hemin for 96 h. Values represent the mean fold change compared to the respective control from 
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GDF15 promotes human fibroblast 
proliferation
Because the proliferation of fibroblasts in BM is one of 
the characteristic features of PMF, we evaluated the effect 
of GDF15 on fibroblasts. Normal human dermal fibroblasts 
(NHDF) were incubated with either rhGDF15 or rhTGF- β1, 
a well- known inducer of tissue fibrosis [36]. With the 
addition of either rhGDF15 or rhTGF- β1, the number of 
NHDFs significantly increased relative to the number of 
unstimulated control cells (Fig. 5A and B). A neutralizing 
antibody for GDF15 significantly reduced the effect of 
rhGDF15 on the proliferation of NHDFs, whereas isotype- 
matched mouse IgG antibodies did not influence NHDF 
growth (Fig. 5C). Next, we focused on the mechanisms 
underlying the effect of GDF15 on NHDF proliferation. 
Because GDF15 is a TGF- β superfamily cytokine, we 
 assumed that it might use the extracellular signal- regulated 
kinase (ERK), Akt, or Smad pathways. NHDFs were treated 
with either rhGDF15 or rhTGF- β1, and ERK1/2 
phosphorylation was analyzed by immunoblotting. ERK1/2 
was significantly phosphorylated by stimulation with 
GDF15 (Fig. 5D). In contrast, the phosphorylation status 
of Akt remained unchanged by GDF15, and the total 
protein and phosphorylated- Smad3 levels were below the 
detection limit (data not shown). These results suggest 
that activation of ERK pathways may play a role in me-
diating the GDF15- induced proliferation of NHDFs.
Because TGF- β1 is known to participate in the process 
of fibrosis and pathogenesis of fibrotic disorders by  affecting 
extracellular matrix (ECM)- related gene expression in fi-
broblasts, we determined whether GDF15 might have 
similar effects. Consistent with the results of previous 
reports, rhTGF- β1 induced mRNA expression of the profi-
brotic genes COL1A1, COL3A1, COL4A1, COL7A1, alpha- 
smooth muscle actin, connective tissue growth factor, and 
TIMP- 1, and suppressed the expression of the antifibrotic 
MMP- 1 gene in NHDFs [37–39]. In contrast, rh GDF15 
had no significant effect on ECM- related gene expression 
Figure 4. Effect of Growth differentiation factor 15 (GDF15) treatment of human BM- MSCs on expansion of HPCs. (A) Schematic representation of 
the experimental procedure used to analyze the effect of GDF15 on the proliferation of CD34+ HPCs cultured in the absence of human BM- MSCs as 
feeders (upper) and on the ability of human BM- MSCs to facilitate the expansion of CD34+ HPCs (lower). (B) Number of HPCs in the absence of feeder 
cells. HPCs were cultured in the absence or presence of 0.5, 5, and 50 ng/mL rhGDF15 for 10 days in the absence of feeder cells, and the cells were 
then counted in a hemocytometer by using Trypan blue exclusion. The results are presented relative to those of the untreated control. Each point 
signifies the mean from five replicates; bars indicate ± SE. (C) Number of total CD45+ hematopoietic cells expanded after 10 days of co- culture with 
either nonstimulated or rhGDF15 (30 ng/mL)- stimulated BM- MSCs, as determined by flow cytometry and a hemocytometer (n = 5). (D) Percentage of 
total CD45+CD34+ hematopoietic cells (left panel), and the ratios of CD38– (middle panel) and CD38+ (right panel) cells among them, expanded after 
10 d of co- culture with either nonstimulated or rhGDF15- stimulated BM- MSCs. SFEM, serum- free expansion medium. *P < 0.05 versus control; 
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Figure 5. Effects of Growth differentiation factor 15 (GDF15) on normal human dermal fibroblasts (NHDFs). (A and B) Effects of rhGDF15 and rhTGF- 
β1 on proliferation of NHDFs. NHDFs were cultured in the absence or presence of (A) 30 ng/mL rhGDF15 or (B) 2 ng/mL rhTGF- β1 for 24, 48, 72, and 
96 h, and the cells were counted with a hemocytometer using Trypan blue exclusion. Each point signifies the mean from five replicates; bars 
indicate ± SE (left panels). (A, right panels) NHDF were visualized using light microscopy after 72 h of rhGDF15 exposure (original magnification, 
×400). (C) Effect of an anti- GDF15 neutralizing antibody on GDF15- induced NHDF proliferation. NHDFs were treated with rhGDF15 in the absence or 
presence of anti- GDF15 neutralizing antibodies (1 μg/mL) or control isotype- matched mouse IgG for 96 h, and the cells were counted with a 
hemocytometer. (D) Immunoblot analysis of ERK1/2 phosphorylation in NHDFs treated with either rhGDF15 (left panels) or rhTGF- β1 (right panels) for 
5, 15, and 30 min. The relative phosphorylation levels of ERK1/2 were normalized to the levels of total ERK1/2 protein and quantified using ImageJ. 
(E) Quantitative real- time polymerase chain reaction analysis examining extracellular matrix (ECM)- related mRNA expression in NHDFs treated with 
rhGDF15 or rhTGF- β1 for 3 days. The fold of increase in each mRNA in the treated group was obtained by normalization to untreated controls. 
COL1A1, collagen type 1 alpha 1; COL3A1, collagen type 3 alpha 1; COL4A1, collagen type 4 alpha 1; COL7A1, collagen type 7 alpha 1; ASMA, 
alpha- smooth muscle actin; CTGF, connective tissue growth factor; MMP- 1, matrix metalloproteinase- 1; TIMP- 1, tissue inhibitor of metalloproteinase- 1. 
Values represents the mean ± SE (n = 3). *P < 0.05 versus control; **P < 0.01 versus control.
in NHDFs (Fig. 5E). These results indicate that GDF15 
promotes the proliferation of fibroblasts but does not 
 affect the mRNA expression of ECM- related genes involved 
in the process of fibrosis.
GDF15 promotes the proliferation and 
osteoblastic differentiation of human 
BM- MSCs
Because osteosclerosis is another characteristic feature of 
PMF and osteoblasts are derived from BM- MSCs, we next 
investigated the effects of GDF15 on the proliferation and 
differentiation of human BM- MSCs. In an in vitro culture 
system, the number of BM- MSCs significantly increased 
after 1 week in the presence of rhGDF15, and this effect 
was concentration- dependent (Fig. 6A and B). We then 
investigated whether GDF15 promotes the differentiation 
of BM- MSCs into osteoblastic lineages. Human BM- MSCs 
exposed to rhGDF15 for 4 weeks exhibited positive Alizarin 
Red S staining, indicating mineralized deposits, whereas 
control human BM- MSCs exhibit a lack of clear staining, 
indicating that GDF15 had the capacity to induce bone 
formation (Fig. 6C). Western blot analysis revealed that 
protein levels of Runx2 and osterix (OSX), representative 
markers of osteoblastic differentiation, were significantly 
elevated in rhGDF15- treated human BM- MSCs compared 
to control cells in this condition (Fig. 6D). Next, we 
examined whether GDF15 affects the adipogenic differ-
entiation of human BM- MSCs. Cells were cultured in the 
presence or absence of rhGDF15 for 2 weeks and stained 
with Oil Red O, which reflects adipogenetic differentia-
tion. There were no significant differences in Oil Red O 
staining between GDF15- treated and untreated cells (data 
not shown).
These in vitro results prompted us to investigate the 
effect of GDF15 on bone formation in a xenograft mouse 
model that we previously established [24, 26, 27, 29, 40, 
41]. Either GDF15 pretreated or untreated human BM- 
MSCs were seeded on HA scaffolds and subcutaneously 
implanted in NOD/SCID mice. After 10 weeks of im-
plantation, the implants were histologically examined. 
The percentage of bone area relative to the total area 
of formed connective tissues in the HA scaffolds was 
significantly higher in GDF15- pretreated human BM- MSC 
implants than in untreated BM-MSC implants (Fig. 6E). 
Taken together, these findings indicate that GDF15 has 
the potential to induce human BM- MSCs to differentiate 
toward the osteoblastic lineage both in vitro and in vivo.
Discussion
In this study, we demonstrated that the concentration of 
serum GDF15 was significantly increased in patients with 
various hematologic malignancies in comparison with 
healthy controls. These results were consistent with those 
of previous reports showing elevated levels of serum GDF15 
in PV, ET, and MM patients [18, 19]. Among the 
 hematologic diseases that we evaluated, PMF showed par-
ticularly high serum GDF15 concentrations.
PMF, the most severe type of BCR-ABL1- negative MPN, 
is characterized by sustained proliferation of abnormal 
megakaryocytes, BM fibrosis, osteosclerosis, extramedullary 
hematopoiesis, splenomegaly, and anemia. These symptoms 
are progressive, and some patients eventually develop acute 
leukemia. The prognosis of patients with this disease is 
generally unfavorable [42]. Blood cells of half of the 
 patients carry JAK2 V617F mutant alleles, whereas mutant 
MPL genes are less common [43]. Clonal expansion of 
abnormal megakaryocytes and stromal reactions caused 
by humoral factors released from these megakaryocytes, 
such as TGF- β, basic fibroblast growth factor (bFGF), 
and platelet- derived growth factor (PDGF), have been 
implicated in the pathogenesis of BM fibrosis in PMF 
[44]. In addition, expression of BMPs, including BMP1, 
BMP6, and BMP7, is elevated in patients in the advanced 
stages of PMF, and megakaryocytes and BM- MSCs are 
considered to be the major sources of BMPs [45]. In 
particular, enhanced expression of BMP6 was observed 
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in the prefibrotic stage of PMF and was shown to be 
critical in the fibrotic switch from early to more advanced 
stages of PMF [45].
Among the cell types in BM, erythroid progenitors, 
macrophages, and MSCs have been shown to produce 
GDF15 [14, 21]. In addition, our results for IHC staining 
indicated that megakaryocytes may be another source of 
GDF15 in BM. The possibility that megakaryocytes 
 absorbed GDF15 from their environment and simply stored 
it in their cytoplasm could not be excluded; however, 
our in vitro HEL cell differentiation assay showed that 
megakaryocytic cells produced GDF15. The remarkably 
elevated serum concentrations of GDF15 in PMF patients 
observed in our study agree with the increased number 
of megakaryocytes observed in PMF.
GDF15 is regarded as a stress cytokine that protects 
cells from various types of damage such as hypoxia. 
Therefore, we initially hypothesized that in PMF, GDF15 
is produced in response to impairment of the hematopoietic 
environment in BM to support hematopoiesis. Consistent 
with this hypothesis, human HPCs were more effectively 
expanded when co- cultured with human BM- MSCs that 
had been pretreated with GDF15 than when co- cultured 
with untreated BM- MSCs. Early- stage osteoblastic cells with 
high expression of Runx2 have been shown to possess 
strong potential to support HPC proliferation [46]. The 
GDF15- induced osteoblastic differentiation that we showed 
in this study may thus enhance the hematopoiesis- 
supporting potential of human BM- MSCs.
Increased fibrous connective tissue levels, one of the 
characteristic features in PMF, are mainly caused by  increased 
production of ECM including collagen and α- smooth muscle 
actin (αSMA). The amount of ECM is determined by not 
only the production of these fibrotic molecules but also 
the production of MMPs that dissolve the ECM and TIMPs 
that inhibit the activity of MMPs [47]. Several studies have 
shown that TGF- β secreted from abnormal megakaryocytes 
activates fibroblasts, promotes ECM deposition, suppresses 
production of MMPs, and leads to BM fibrosis in PMF 
[39, 48]. Similarly, PDGF and bFGF have also been im-
plicated in BM fibrosis through proliferation of fibroblasts 
and stromal cells and have been shown to support vascular 
endothelial cell growth [49]. The results of this study dem-
onstrated that GDF15 protein is highly expressed in mega-
karyocytes and enhances the proliferation of both fibroblasts 
and MSCs; however, in contrast to TGF- β, it does not 
alter the expression of ECM- related genes in vitro. Recently, 
Lambrecht et al. did not observe differences in the devel-
opment of pulmonary fibrosis between wild- type and 
GDF15- deficient mice [50]. Therefore, GDF15 may not play 
essential roles in the development of tissue fibrosis.
Osteosclerosis, a bone disorder characterized by abnormal 
bone thickening and increased bone mass, is another com-
mon pathological feature of PMF. Osteosclerosis occurs as 
a result of imbalances in bone remodeling, which is a process 
of bone formation by osteoblasts and bone resorption by 
osteoclasts. Osteoblasts are derived from mesenchymal pro-
genitors, which are multipotent nonhematopoietic cells ca-
pable of differentiating into a variety of cell types, including 
osteoblasts, adipocytes, and chondrocytes, by the actions of 
growth factors produced locally or present in the circulation 
[51]. Although GDF15 belongs to the BMP family, its role 
in bone remodeling is controversial. Subcutaneous implanta-
tion of Chinese hamster ovary cells that expressed recom-
binant GDF15 was shown to induce cartilage formation and 
the early stages of  endochondral bone formation [5]. In an 
in vitro experiment, GDF15 was reported to inhibit osteo-
clastic differentiation from RAW264.7 macrophages and BM 
precursors by M- CSF/RANKL in a concentration- dependent 
manner [52]. In contrast, hypoxia- induced overexpression 
of GDF15 in mice was reported to promote osteoclastic 
differentiation, thereby reducing bone volume [53]. 
Wakchoure et al. inoculated nude mice with DU- 145 human 
prostatic cancer cells overexpressing GDF15 and observed 
Figure 6. Effects of GDF15 on proliferation and osteoblastic differentiation of human bone marrow- derived mesenchymal stromal cells (BM- MSC). 
(A) Human BM- MSCs were cultured in the absence or presence of 30 ng/mL rhGDF15 for 4, 6, and 8 days, and the cells were counted in a 
hemocytometer. Each point signifies the mean from five replicates; bars indicate ± SE. (B) Human BM- MSCs cultured in the presence of 0, 1, and 
30 ng/mL rhGDF15 for 8 days were counted in a hemocytometer. The results are presented relative to those of untreated controls (left panel), as 
visualized using light microscopy (right panels, original magnification ×400). Bars indicate ± SE. (C and D) GDF15- induced osteoblastic differentiation 
of BM- MSCs. (C) Human BM- MSCs were treated with rhGDF15 (30 ng/mL) for 4 weeks. Mineralized deposits indicated by Alizarin Red S staining were 
quantified using ImageJ in five different fields viewed at ×100 magnification. The results are presented relative to those of untreated controls (left 
panel), as visualized using light microscopy (right panels; magnification, ×100). (D) RUNX2 and osterix (OSX) protein expression in GDF15- treated 
BM- MSCs were analyzed by immunoblotting. The expression levels were normalized against β- actin protein levels and quantified using ImageJ. The 
results are presented relative to those of untreated controls. (E) In vivo bone formation assays. (Upper panel) Schematic representation of the 
experimental procedure used to analyze the effects of GDF15 on bone formation in a xenograft mouse model. Human BM- MSCs treated with 
rhGDF15 (30 ng/mL) for 3 days were subcutaneously transplanted into NOD/SCID mice (n = 4) using a hydroxyapatite- poly d, l- lactic- co- glycolic acid 
composite block type scaffold (HA scaffold) as a carrier and harvested 10 weeks later. (Lower right and left panels) Representative microscopic images 
and quantitative measurement of bone formation areas in sections of human BM- MSC implants stained with hematoxylin and eosin. HA, 
hydroxyapatite; B, bone. Bar = 50 μm. The results are expressed as the ratio of the total bone area to the total implant area, quantified using ImageJ 
in five different fields viewed at ×100 magnification (lower middle panel). Bars indicate ± SE. *P < 0.05; **P < 0.01.
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both enhanced osteoblast differentiation and osteoclast num-
bers at sites of bone metastases [54]. The results of our 
study indicate that exposure to very high concentrations of 
GDF15 induced mineral depositions and expression of the 
osteoblastic lineage markers Runx2 and osterix in BM- MSCs 
in vitro and that pretreatment of human BM- MSCs with 
rhGDF15 enhanced bone formation in a xenograft mouse 
model, indicating that GDF15 has the potential to promote 
osteoblastic differentiation under certain conditions.
Considering that GDF15 is produced in response to cel-
lular stress and acts to protect cells and tissues in various 
situations, it is likely to be produced in response to the 
impairment of hematopoietic environment in PMF [55, 56]. 
In the early (prefibrotic and hypercellular) stages of PMF, 
GDF15 derived from megakaryocytes may support hemat-
opoiesis by affecting BM- MSCs as a component of the BM 
niche. However, our results also indicate that GDF15 pro-
motes the differentiation of BM- MSCs toward the osteoblastic 
lineage under certain conditions. Therefore, in advanced 
(fibrotic and ostesclerotic) stages, GDF15 may contribute 
to the development of BM fibrosis and osteosclerosis by 
accelerating the growth of fibroblasts and promoting the 
osteoblastic differentiation of BM- MSCs (Fig. S3).
In summary, we demonstrated that serum GDF15 con-
centrations in patients with PMF are remarkably elevated, 
and in BM, GDF15 is predominantly expressed by mega-
karyocytes. Our in vitro and in vivo studies suggest that 
GDF15 may be involved in the pathogenesis of PMF by 
promoting osteoblastic differentiation of BM- MSCs. 
Further studies are needed to assess the value of GDF15 
as a new biomarker for evaluating treatment response 
and monitoring disease progression in hematologic 
 malignancies including PMF, and to understand the precise 
roles of this cytokine in the BM microenvironment in 
both physiological and pathological conditions.
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Supporting Information
Additional supporting information may be found in the 
online version of this article:
Figure S1. Histological examination of growth differentia-
tion factor 15 (GDF15) expression in bone marrow (BM) 
clots without decalcification. (A) BM clot sections with 
normal morphology obtained from patients with localized 
gastric cancer. GDF15 is principally expressed by mega-
karyocytes. Original magnification, ×400.
Figure S2. In vitro differentiation of HEL cells. HEL cells 
were cultured in the presence of 10 μmol/L diosgenin, 
50 μmol/L hemin, or 10 nmol/L PMA for 144 h, which 
was followed by flow- cytometric analyses of cell surface 
expression of CD41 and CD235a. PE- conjugated mouse 
anti- human CD41 (Cosmo Bio, Tokyo, Japan) and CD235a 
(BD Biosciences, Franklin Lakes, NJ) antibodies were used. 
Shaded purple areas represent histograms of isotype of 
control experiments.
Figure S3. A hypothetical scheme for the roles of GDF15 
in primary myelofibrosis. GDF15 may be produced in 
response to the impairment of hematopoietic environment. 
In the early prefibrotic stage, GDF15 derived from mega-
karyocytes may support hematopoiesis by affecting BM-
MSCs as a component of the BM niche. In the fibrotic 
stages, however, GDF15 may contribute to the development 
of BM fibrosis by accelerating the growth of fibroblasts 
together with TGF- β- induced ECM production. In a more 
advanced stage, excessive or prolonged GDF15 production 
may lead to the development of osteosclerosis by promot-
ing osteoblastic differentiation of BM-MSCs. PMF, primary 
myelofibrosis; MK, Megakaryocyte; MSC, mesenchymal 
stroma cell; HPC, hematopoietic progenitor cell; GDF15, 
growth differentiation factor 15; TGF- β transforming growth 
factor, β- ECM, extracellular matrix; BM, bone marrow.
Table S1. Primer sequences of the target genes used in 
quantitative RT- PCR.
Table S2. Clinical features of patients with myeloprolifera-
tive neoplasms. 
